Chronic Obstructive Pulmonary Disease News and Research RSS Feed - Chronic Obstructive Pulmonary Disease News and Research

The World Health Organisation (WHO) has described Chronic Obstructive Pulmonary Disorder (COPD) as a global epidemic; an estimated 210 million people have COPD worldwide and more than 3 million people died of the condition in 2005, which is equal to 5% of all deaths globally that year. Total deaths from COPD are projected to increase by more than 30% in the next 10 years without interventions to cut risks, particularly exposure to tobacco smoke.
UofL study investigates safety, effectiveness of EBV for treating emphysema symptoms

UofL study investigates safety, effectiveness of EBV for treating emphysema symptoms

The University of Louisville has launched a research trial to study an investigational medical device designed to aid patients with emphysema by shutting off the diseased part of the lung. UofL is the only site in Kentucky among 14 nationwide testing the device. [More]
Study examines effects of beetroot juice on physical function of COPD patients

Study examines effects of beetroot juice on physical function of COPD patients

A Wake Forest University study to investigate the effects of acute beetroot juice ingestion on the exercise capacity of COPD patients shows some promise, but a larger clinical trial is needed to verify results. [More]
Johns Hopkins researchers propose novel cancer-fighting strategy

Johns Hopkins researchers propose novel cancer-fighting strategy

Existing cancer therapies are geared toward massacring tumor cells, but Johns Hopkins researchers propose a different strategy: subtly hardening cancer cells to prevent them from invading new areas of the body. They devised a way of screening compounds for the desired effect and have identified a compound that shows promise in fighting pancreatic cancer. [More]
TERT mutations may make smokers more susceptible to emphysema

TERT mutations may make smokers more susceptible to emphysema

Mutations in a gene that helps repair damaged chromosome ends may make smokers — especially female smokers — more susceptible to emphysema, according to results of a new study led by Johns Hopkins Kimmel Cancer Center researchers. [More]
Clementia secures additional $10 million to support development of palovarotene for treatment of FOP

Clementia secures additional $10 million to support development of palovarotene for treatment of FOP

Clementia Pharmaceuticals, Inc. today announced that it has secured an additional $10 million from current investors to support development of the company's lead compound palovarotene for the treatment of fibrodysplasia ossificans progressive (FOP). [More]
Oral budesonide suspension offers hope for pediatric patients with EoE

Oral budesonide suspension offers hope for pediatric patients with EoE

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. [More]
Gene variations predispose mestizo Mexican population to develop severe form of COPD

Gene variations predispose mestizo Mexican population to develop severe form of COPD

A study by Ramcés Falfán-Valencia, researcher at the National Institute of Respiratory Diseases, found that the mestizo Mexican population has a number of variations in certain genes that predispose them to develop the most severe form of chronic obstructive pulmonary disease (COPD). [More]
Kaiser Permanente study: Self-reported exercise lowers blood pressure, blood glucose levels

Kaiser Permanente study: Self-reported exercise lowers blood pressure, blood glucose levels

Self-reported moderate to vigorous exercise was associated with lower blood pressure and blood glucose levels in a Kaiser Permanente study published in the journal Preventing Chronic Disease. [More]
University Hospital Bonn to validate accuracy of VolitionRx’s Nucleosomics technology in lung cancer

University Hospital Bonn to validate accuracy of VolitionRx’s Nucleosomics technology in lung cancer

VolitionRx Limited, a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced that the University Hospital Bonn in Germany will initiate a clinical confirmatory study to assess VolitionRx’s proprietary Nucleosomics platform technology for the diagnosis of lung cancer through a blood test in individuals. [More]
Andor's Komet software used to automatically score modified 3D 'Comet' assay results

Andor's Komet software used to automatically score modified 3D 'Comet' assay results

With cancer rates rising worldwide, and Cancer Research UK predicting that the lifetime risk of cancer will reach 50% by 2027, the need for early diagnosis is overwhelming. Now, a British research group has published details of a simple empirical test to detect any early-stage cancer, relying on Andor's Komet software to automatically score the modified 3D 'Comet' assay results. [More]
Disease-associated malnutrition imposes economic burden on society

Disease-associated malnutrition imposes economic burden on society

Even in food-abundant industrialized countries like the U.S., an alarming number of people, particularly seniors, are in a state of diseased-associated malnutrition. Because of the impact on patient health, disease-associated malnutrition imposes a significant economic burden on society of $157 billion per year, according to new research published in a supplemental issue of the Journal of Parenteral and Enteral Nutrition and supported by Abbott. [More]
U-M startup company Imbio gets FDA approval to market Lung Density Analysis for COPD

U-M startup company Imbio gets FDA approval to market Lung Density Analysis for COPD

A technology that started in a University of Michigan Medical School lab may soon help lung disease patients around the world breathe a little easier, by helping their doctors make a clearer diagnosis and more individualized treatment plan. [More]
Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Apellis Pharmaceuticals, Inc., a leading biotechnology company applying immunotherapy to autoimmune disease, today announced that it has completed a $33M private placement of its Series C Preferred Stock. [More]
Clementia's palovarotene receives FDA Fast Track designation for FOP treatment

Clementia's palovarotene receives FDA Fast Track designation for FOP treatment

Clementia Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to palovarotene, which is being developed for the treatment of fibrodysplasia ossificans progressiva (FOP). [More]
Persistent eosinophilia common in COPD

Persistent eosinophilia common in COPD

More than one-third of patients with chronic obstructive pulmonary disease have persistent eosinophilia, researchers report in the European Respiratory Journal. [More]
Better evidence needed for relationship between exercise and COPD

Better evidence needed for relationship between exercise and COPD

Researchers call for high-quality studies investigating the relationship between physical activity and chronic obstructive pulmonary disease after their systematic review found the level of evidence to be poor. [More]
Study shows effectiveness of VolitionRx’s NuQ test in detecting lung cancer in blood and sputum

Study shows effectiveness of VolitionRx’s NuQ test in detecting lung cancer in blood and sputum

VolitionRx Limited, a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced that data from its pilot lung cancer study will be presented at the Science for Business BioWin Day 2014, being held November 26, 2014 in Louvain-la-Neuve, Belgium. [More]
Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Clementia Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation for palovarotene, the company's lead product candidate, for the treatment of fibrodysplasia ossificans progressiva (FOP). [More]
Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Apellis Pharmaceuticals announced today that it entered into an agreement to acquire Potentia Pharmaceuticals. [More]
Nutrition treatment for older COPD patients shows better outcomes

Nutrition treatment for older COPD patients shows better outcomes

People aged 65 and older, who were being treated for chronic obstructive pulmonary disease (COPD) in the hospital and received nutrition treatment (oral nutrition supplements) had reduced lengths of stay, hospital costs and chances of returning to the hospital within 30-days, according to a study published in CHEST. [More]